View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 26, 2021updated 12 Jul 2022 11:22am

Leidos to conduct clinical trials for Covid-19 therapeutics

The Defense Threat Reduction Agency (DTRA) in the US has awarded a new project agreement to Leidos to conduct clinical trials for Covid-19 therapeutics.

The Defense Threat Reduction Agency (DTRA) in the US has awarded a new project agreement to Leidos to conduct clinical trials for Covid-19 therapeutics.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The cost-plus-fixed-fee agreement, which holds a $22m base value and 24 months of performance period, was awarded through the Medical CBRN Defense Consortium.

Through the new contract, Leidos plans to use a new clinical trial prototype, which uses an electronic data capture system to collect, evaluate and assess symptom severity.

This will enable real-time data collection to support rapid initiation, amendment and evaluation of clinical studies.

Leidos will use the new prototype to simultaneously conduct two clinical studies using new drug combinations for the treatment of Covid-19.

Designed to analyse the requirement of additional patients, Leidos trial prototype aims to provide quick evaluations and improvements as the study advances.

Leidos stated that these evaluations made by the new prototype could improve potential Phase III studies and also to demonstrate the efficacy using the selected drug combination.

Leidos Health Group president Liz Porter said: “This award reinforces our commitment to fighting this deadly pandemic.

“We are proud to conduct these clinical trials and support our customers’ mission to develop life-saving drugs, vaccines and therapeutics for the men and women of our armed forces.”

For this prototype project, the company will partner with Personal Health Insights, Syneos Health and SCOPE International USA.

Furthermore, Leidos noted that these clinal trials will help to pursue enhancements to military success by improving the long-term lung function and reducing neurocognitive deficits caused due to Covid-19.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena